Dutch venture capital firm BioGeneration Ventures is looking to expand the portfolio of early-stage, human health-focused firms in its BGV III fund after securing €66m to invest. It has already invested in four companies – one German, three Dutch – and expects to invest in 15 in total. It has beaten its initial target for BGV III of €50m and expects to reach the maximum fund size of €75m by the end of 2017. This compares with its two previous funds of €17m in 2006 and €15m in 2012.
Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target
Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.
More from Financing
• By
As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.
• By
Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.
• By
Private Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.
• By
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
More from Business
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.